How were Versartis' earnings last quarter?

Versartis, Inc. (NASDAQ:VSAR) posted its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $0.69.

What other stocks do shareholders of Versartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Versartis investors own include Progenics Pharmaceuticals (PGNX) , ZIOPHARM Oncology (ZIOP) , Bausch Health Companies (BHC) , Genocea Biosciences (GNCA) , Novavax (NVAX) , Cara Therapeutics (CARA) , Flexion Therapeutics (FLXN) , SCYNEXIS (SCYX) and Synergy Pharmaceuticals (SGYP) .

NASDAQ:VSAR

Versartis (VSAR) Stock Price, News & Analysis

→ Elon Musk’s ChatGPT Could Soon Mint New Millionaires (From InvestorPlace) (Ad)

Free VSAR Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.18
▼
$1.30
50-Day Range: $1.19
▼
$1.19
52-Week Range: $1.14
▼
$2.76

Volume: 349,963 shs
Average Volume: 479,436 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Versartis alerts:

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About Versartis Stock (NASDAQ:VSAR)

Aravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

VSAR Stock News Headlines

July 21, 2023 | thestreet.com

16 Biopharma Companies Besides Medivation That Are Attractive Targets

December 28, 2022 | thestreet.com

Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

October 11, 2022 | finance.yahoo.com

Zluri Hires Todd Dekkinga as Chief Information Security Officer - Yahoo Finance

May 9, 2022 | seekingalpha.com

Ascendis Pharma: Biotech Bear Provides Attractive Entry Point - Seeking Alpha

March 21, 2022 | thestreet.com

Versartis Price Gains on Drug Approval, eHealth Rises: Tech Winners & Losers

September 22, 2021 | prnewswire.com

Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm - PRNewswire

September 3, 2021 | finance.yahoo.com

Cidara Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, and Shane Ward as Chief Legal Officer and Corporate Secretary - Yahoo Finance

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

September 2, 2021 | streetinsider.com

Cidara Therapeutics (CDTX) Appoint Preetam Shah as CFO and CBO, and Shane Ward as Chief Legal Officer and Corporate Secretary - StreetInsider.com

July 22, 2021 | entrepreneur.com

3 Biotech Stocks Wall Street Predicts Will Rally by More Than 170% - Entrepreneur

See More Headlines

Receive VSAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Versartis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/07/2018
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VSAR
CUSIP: N/A
CIK: 1513818
Web: www.versartis.com
Phone: (936) 355-1910
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Optionable
Beta: N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Gail Frances McIntyre
President, Chief Executive Officer & Director
Vinay Shah
Chief Financial Officer
Reshma Rangwala
Chief Medical Officer
Amy Franke
Vice President-Clinical Operations
Randy Anderson
Senior Vice President-Data Sciences

Key Competitors

View All Competitors

VSAR Stock Analysis - Frequently Asked Questions

How were Versartis' earnings last quarter?: Versartis, Inc. (NASDAQ:VSAR) posted its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $0.69.
What other stocks do shareholders of Versartis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Versartis investors own include Progenics Pharmaceuticals (PGNX), ZIOPHARM Oncology (ZIOP), Bausch Health Companies (BHC), Genocea Biosciences (GNCA), Novavax (NVAX), Cara Therapeutics (CARA), Flexion Therapeutics (FLXN), SCYNEXIS (SCYX) and Synergy Pharmaceuticals (SGYP).

This page (NASDAQ:VSAR) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Versartis (VSAR) Stock Price, News & Analysis

About Versartis Stock (NASDAQ:VSAR)

VSAR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

VSAR Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info